Pennsylvania is currently home to 3311 active clinical trials, seeking participants for engagement in research studies. These trials take place at a variety of cities in the state, including Philadelphia, Pittsburgh, Hershey and Allentown. Whether you're a healthy volunteer interested in paid medical research or someone seeking trials related to a specific condition, the state offers a diverse array of opportunities in your vicinity.
Phase 2 Study to Evaluate Safety and Efficacy of Cretostimogene Grenadenorepvec in High-Risk NMIBC
NCT06567743
Recruiting
This is a Phase 2, Multi-Arm, Multi-Cohort, Open-Label Study to Evaluate the Safety and Efficacy of Cretostimogene Grenadenorepvec in Participants with High-Risk Non-Muscle-Invasive Bladder Cancer.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/17/2025
Locations: Midlantic Urology (Solaris), Bala-Cynwyd, Pennsylvania
Conditions: High-Risk Non-Muscle-Invasive Bladder Cancer
Register for Updates
A Study of Lifileucel (Tumor-infiltrating Lymphocytes) in Adults With Advanced Endometrial Cancer.
NCT06481592
Recruiting
The purpose of this study is to investigate the efficacy and safety of the lifileucel regimen in participants with previously treated endometrial cancer.
Gender:
FEMALE
Ages:
Between 18 years and 70 years
Trial Updated:
03/17/2025
Locations: Allegheny Health, Pittsburgh, Pennsylvania
Conditions: Endometrial Cancer
Register for Updates
Saruparib (AZD5305) Plus Camizestrant Compared With CDK4/6 Inhibitor Plus Endocrine Therapy or Plus Camizestrant in HR-Positive, HER2-Negative (IHC 0, 1+, 2+/ ISH Non-amplified), BRCA1, BRCA2, or PALB2m Advanced Breast Cancer
NCT06380751
Recruiting
The primary objective of the study is to measure efficacy of saruparib (AZD5305) plus camizestrant compared with physician's choice CDK4/6i plus ET in patients with BRCA1, BRCA2, or PALB2m, HR-positive, HER2-negative (defined as IHC 0, 1+, 2+/ ISH non-amplified) advanced breast cancer.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/17/2025
Locations: Research Site, Hershey, Pennsylvania
Conditions: Advanced Breast Cancer
Register for Updates
A Phase 1a/1b Study of ACTM-838 in Patients With Advanced Solid Tumors
NCT06336148
Recruiting
This is a first in human (FIH) 2-part study using ACTM-838 in patients with advanced solid tumors resistant to standard of care treatment. Part 1a will evaluate dose escalation and Part 1b will evaluate dose expansion.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/17/2025
Locations: UPMC Hillman Cancer Center, 5115 Centre Ave, Pittsburgh, Pennsylvania
Conditions: Solid Tumor
Register for Updates
Expanding Liver Transplant Immunosuppression Minimization Via Everolimus
NCT06280950
Recruiting
This is a study to determine the safety, efficacy, and tolerability of taking away the anti-rejection medicine, tacrolimus, in liver transplant recipients in conjunction with everolimus monotherapy to preserve renal function. Two hundred - seventy (270) subjects will be randomized 2:1 into one of two groups between 2-3 months post-transplant. Seventy participants will be placed into an observational group and will remain on their current post-transplant medications. The duration of the study fro... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/17/2025
Locations: University of Pennsylvania (Site #: 71111), Philadelphia, Pennsylvania
Conditions: Liver Transplant
Register for Updates
A Study to Investigate the Effect of Baxdrostat on Ambulatory Blood Pressure in Participants With Resistant Hypertension
NCT06168409
Recruiting
This is a Phase III, multicenter, randomized, double-blind, placebo-controlled, parallel group study to evaluate the safety, tolerability and the effect of 2 mg Baxdrostat vs. placebo, administered QD orally, on the reduction of SBP, measured by average 24-hour ABPM in 212 participants with rHTN (defined as seated SBP ≥ 140 mmHg at Screening and mean ambulatory SBP ≥ 130 mmHg at baseline, despite a stable regimen of ≥ 3 antihypertensive agents, one of which is a diuretic).
Gender:
ALL
Ages:
Between 18 years and 130 years
Trial Updated:
03/17/2025
Locations: Research Site, Langhorne, Pennsylvania
Conditions: Resistant Hypertension
Register for Updates
Study of Lurbinectedin in Combination With Doxorubicin Versus Doxorubicin Alone as First-line Treatment in Participants With Metastatic Leiomyosarcoma
NCT06088290
Recruiting
The primary objective of this phase IIb/III study is to evaluate whether the combination of lurbinectedin plus doxorubicin given as first line treatment for metastatic leiomyosarcoma (LMS) prolongs the progression-free survival (PFS) by Independent Review Committee (IRC) when compared to doxorubicin administered as a single agent.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/17/2025
Locations: University of Pennsylvania Abramson Cancer Center, Philadelphia, Pennsylvania
Conditions: Leiomyosarcoma
Register for Updates
Study to Assess the Safety and Efficacy of OCU410 for Geographic Atrophy
NCT06018558
Recruiting
This is a Phase 1/2 Study to Assess the Safety and Efficacy of OCU410 for Geographic Atrophy Secondary to Dry Age-Related Macular Degeneration (AMD). This is a multicenter study, which will be conducted in two phases and will enroll up to a total of 63 subjects.
Gender:
ALL
Ages:
50 years and above
Trial Updated:
03/17/2025
Locations: The University of Pittsburgh, Pittsburgh, Pennsylvania
Conditions: Geographic Atrophy
Register for Updates
Trial to Increase FEP Attendance
NCT05967195
Recruiting
Individuals with first-episode psychosis (FEP) are at high-risk for several poor functional and clinical outcomes, including suicide. Coordinated Specialty Care (CSC) is a multidisciplinary, team-based intervention known to improve such outcomes, including suicide risk. However, 30-50% of patients disengage from CSC, thereby limiting its impact. This pilot study will develop and test feasibility of a behavioral change program that uses moderate financial incentives to encourage treatment engagem... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/17/2025
Locations: PEACE Program, Horizon House, Inc., Philadelphia, Pennsylvania
Conditions: First-Episode Psychosis
Register for Updates
Assessment of Biomarker-Guided CNI Substitution In Kidney Transplantation
NCT05917522
Recruiting
800 adult first time kidney transplant recipients will be enrolled in the Observational Study and followed to evaluate their Human Leukocyte Antigen (HLA)-DR/DQ molecular mismatch (mMM) score as a risk-stratifying prognostic biomarker. Six months after transplant the study will identify those who meet the eligibility criteria for the Nested Randomized Control Trial (RCT). 300 eligible subjects will be randomized 2:1 to abatacept or Standard of care (SOC) in the randomization and followed for 18... Read More
Gender:
ALL
Ages:
Between 18 years and 70 years
Trial Updated:
03/17/2025
Locations: University of Pennsylvania Medical Center: Transplantation, Philadelphia, Pennsylvania
Conditions: Kidney Transplant
Register for Updates
Liquid Biopsy Based NGS in Newly Diagnosed NSCLC
NCT05853887
Recruiting
This study expands the application of an electronic health record (EHR) "nudge" used to prompt physicians' clinical practice to order molecular testing at the time of initial diagnosis for patients with specific types of advanced lung cancer. The primary goal is to have these test results available prior to starting treatment so that physicians can make molecularly-informed treatment decisions. The second goal is to better understand factors that contribute to whether or not the EHR-nudge implem... Read More
Gender:
ALL
Ages:
All
Trial Updated:
03/17/2025
Locations: Penn Medicine Lancaster General Health, Lancaster, Pennsylvania
Conditions: Non Small Cell Lung Cancer Metastatic, Newly Diagnosed NSCLC, Non-Squamous Non-Small Cell Neoplasm of Lung
Register for Updates
Phenotyping Interstitial Cystitis/Bladder Pain Syndrome (IC/BPS) by Intravesical Contrast Enhanced - Magnetic Resonance Imaging (ICE-MRI) Bladder Permeability Assay
NCT05811377
Recruiting
Each participant will be asked to participate in this research study which distinguishes different types of Interstitial Cystitis/Bladder Pain Syndrome. Research studies include only people who wish to participate. The study team members will explain the study to each participant, and all questions about the study will be answered. Each participant will be given adequate time when deciding to participate in this study. Should the participant consent to participate, then the participant will agre... Read More
Gender:
ALL
Ages:
Between 18 years and 80 years
Trial Updated:
03/17/2025
Locations: UPMC Magee Women's Hospital, Pittsburgh, Pennsylvania
Conditions: IC - Interstitial Cystitis
Register for Updates